Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of the COVID-19 Pandemic on Cancer Clinical Trials.
Boughey JC, Snyder RA, Kantor O, Zheng L, Chawla A, Nguyen TT, Hillman SL, Hahn OM, Mandrekar SJ, Roland CL. Boughey JC, et al. Among authors: hillman sl. Ann Surg Oncol. 2021 Nov;28(12):7311-7316. doi: 10.1245/s10434-021-10406-2. Epub 2021 Jul 8. Ann Surg Oncol. 2021. PMID: 34236550 Free PMC article.
CT screening for lung cancer: five-year prospective experience.
Swensen SJ, Jett JR, Hartman TE, Midthun DE, Mandrekar SJ, Hillman SL, Sykes AM, Aughenbaugh GL, Bungum AO, Allen KL. Swensen SJ, et al. Among authors: hillman sl. Radiology. 2005 Apr;235(1):259-65. doi: 10.1148/radiol.2351041662. Epub 2005 Feb 4. Radiology. 2005. PMID: 15695622
Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer.
Ma CX, Nair S, Thomas S, Mandrekar SJ, Nikcevich DA, Rowland KM, Fitch TR, Windschitl HE, Hillman SL, Schild SE, Jett JR, Obasaju C, Adjei AA; North Central Cancer Treatment Group; Mayo Clinic; Eli Lilly & Company. Ma CX, et al. Among authors: hillman sl. J Clin Oncol. 2005 Sep 1;23(25):5929-37. doi: 10.1200/JCO.2005.13.953. J Clin Oncol. 2005. PMID: 16135464 Clinical Trial.
Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51).
Johnson EA, Marks RS, Mandrekar SJ, Hillman SL, Hauge MD, Bauman MD, Wos EJ, Moore DF, Kugler JW, Windschitl HE, Graham DL, Bernath AM Jr, Fitch TR, Soori GS, Jett JR, Adjei AA, Perez EA. Johnson EA, et al. Among authors: hillman sl. Lung Cancer. 2008 May;60(2):200-7. doi: 10.1016/j.lungcan.2007.10.003. Epub 2007 Nov 28. Lung Cancer. 2008. PMID: 18045731 Clinical Trial.
Endpoints in phase II trials for advanced non-small cell lung cancer.
Mandrekar SJ, Qi Y, Hillman SL, Allen Ziegler KL, Reuter NF, Rowland KM Jr, Kuross SA, Marks RS, Schild SE, Adjei AA. Mandrekar SJ, et al. Among authors: hillman sl. J Thorac Oncol. 2010 Jan;5(1):3-9. doi: 10.1097/JTO.0b013e3181c0a313. J Thorac Oncol. 2010. PMID: 19884856 Free PMC article.
The impact of adjuvant brachytherapy with sublobar resection on pulmonary function and dyspnea in high-risk patients with operable disease: preliminary results from the American College of Surgeons Oncology Group Z4032 trial.
Fernando HC, Landreneau RJ, Mandrekar SJ, Hillman SL, Nichols FC, Meyers B, DiPetrillo TA, Heron D, Jones DR, Daly BD, Starnes SL, Hatter JE, Putnam JB. Fernando HC, et al. Among authors: hillman sl. J Thorac Cardiovasc Surg. 2011 Sep;142(3):554-62. doi: 10.1016/j.jtcvs.2010.10.061. Epub 2011 Jul 2. J Thorac Cardiovasc Surg. 2011. PMID: 21724195 Free PMC article. Clinical Trial.
Thirty- and ninety-day outcomes after sublobar resection with and without brachytherapy for non-small cell lung cancer: results from a multicenter phase III study.
Fernando HC, Landreneau RJ, Mandrekar SJ, Hillman SL, Nichols FC, Meyers B, DiPetrillo TA, Heron DE, Jones DR, Daly BD, Starnes SL, Tan A, Putnam JB. Fernando HC, et al. Among authors: hillman sl. J Thorac Cardiovasc Surg. 2011 Nov;142(5):1143-51. doi: 10.1016/j.jtcvs.2011.07.051. Epub 2011 Aug 26. J Thorac Cardiovasc Surg. 2011. PMID: 21872277 Free PMC article. Clinical Trial.
57 results